CD274 and non-small cell lung carcinoma: Therapy with monoclonal antibodies directed against PD-1 or its corresponding ligand, PD-L1, has yielded impressive results in recent clinical trials, and it is a promising new treatment option for selected patients with advanced NSCLC [2].